Successful Treatment of Persistent Burkholderia cepacia Complex Bacteremia with Ceftazidime-Avibactam

Antimicrob Agents Chemother. 2018 Mar 27;62(4):e02213-17. doi: 10.1128/AAC.02213-17. Print 2018 Apr.

Abstract

We report our clinical experience treating a 2-month-old infant with congenital diaphragmatic hernia who experienced prolonged bacteremia with Burkholderia cepacia complex (Bcc) despite conventional antibiotic therapy and appropriate source control measures. The infection resolved after initiation of ceftazidime-avibactam. Whole-genome sequencing revealed that the isolate most closely resembled B. contaminans and identified the mechanism of resistance that likely contributed to clinical cure with this agent. Ceftazidime-avibactam should be considered salvage therapy for Bcc infections if other treatment options have been exhausted.

Keywords: Burkholderia cepacia complex; bacteremia; ceftazidime-avibactam; whole-genome sequencing.

Publication types

  • Case Reports
  • Research Support, N.I.H., Extramural

MeSH terms

  • Anti-Bacterial Agents / therapeutic use*
  • Azabicyclo Compounds / therapeutic use*
  • Bacteremia / drug therapy*
  • Bacteremia / microbiology*
  • Burkholderia cepacia complex / drug effects*
  • Burkholderia cepacia complex / pathogenicity*
  • Ceftazidime / therapeutic use*
  • Drug Combinations
  • Female
  • Humans
  • Infant
  • Microbial Sensitivity Tests

Substances

  • Anti-Bacterial Agents
  • Azabicyclo Compounds
  • Drug Combinations
  • avibactam, ceftazidime drug combination
  • Ceftazidime